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Metastatic involvement of gastrointestinal tract from breast cancer is a rare event. We report the case of a 61-year-old woman
presentingwith bowel obstruction, related tometastasis of a primary breast cancer she had 12 years earlier (a triple-negative invasive
ductal carcinoma treated with surgery and chemotherapy). Bowel obstruction was caused by a 20-centimeter tumor in the jejunum,
involving also the transverse colon.The patient underwent en bloc resection of tumor with jejunum and transverse bowel segment
and received adjuvant chemotherapywith carboplatin and paclitaxel. Twentymonths later, she was alive without disease recurrence.
1. Introduction
Breast cancer is themost commonmalignancy in women and
the second main cause of cancer-related deaths [1]. Approxi-
mately 5% to 10% of breast cancers aremetastatic at diagnosis,
and 20–50%of patientswill developmetastatic disease during
their lifetime [2], but the incidence of subclinical distant
metastases is probably higher, as shown by autopsy series [3].
Metastases of breast cancer are commonly found in bone,
liver, lungs, and brain. It rarelymetastasizes to the gastrointes-
tinal tract (GIT), with just a few cases of such metastases
reported in the literature [4]. Although breast cancer is one
of the few tumors metastasizing to the GIT, along with mela-
noma, ovarian cancer, and bladder cancer [5], this is still a
rare event [6].
Metastatic patterns of invasive lobular carcinoma (LC)
and invasive ductal carcinoma (DC) usually differ, and LC
is more prone to metastasize to the GIT [7]. Nowadays,
with longer survival due to advances in treatment, metastatic
spreadmay occur several years after primary surgical and sys-
temic treatment. In this regard, we report the case of a patient
with a single breast cancermetastasis to the jejunum, present-
ing with bowel obstruction 12 years after her initial diagnosis.
2. Presentation of Case
This is a 61-year-old woman with previous history of locally
advanced left breast cancer diagnosed in 2002. She had
four cycles of neoadjuvant chemotherapy with doxorubicin
(60mg/m2) and cyclophosphamide (600mg/m2) between
September 27 and November 29, followed by lumpectomy
with ipsilateral axillary lymph node dissection in Decem-
ber 26, 2002. Histopathological examination of the tumor
revealed invasive ductal carcinoma (IDC), histologic grade
III, classified as ypT2N3cM0, stage IIIC. Immunohistochem-
ical staining was negative for estrogen receptor (ER), progest-
erone receptor (PgR), and human epidermal growth factor
receptor 2 (HER2). She had adjuvant chemotherapy with four
cycles of paclitaxel (80mg/m2) between January 31 and April
04, 2003, and adjuvant radiotherapy 50Gy to her left breast,
axillary, and supraclavicular areas and an additional 10Gy
boost to the primary tumor site, finished on June 28, 2003.
She has been disease-free for the last 12 years.
This woman presented to our Emergency Department in
July 31, 2014, with a 2 months’ history of colicky abdom-
inal pain after meals, worsening constipation, abdominal
distension, unintentional weight loss of 5 Kg, and tiredness.
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Figure 1: Tumor aspects in CT scan and in resected specimen.
The physical examination revealed a palpable mass at the
right abdominal quadrants. Laboratory tests showed anaemia
(haemoglobin count of 8.4 g/dL). A computed tomography
(CT) scan was performed and revealed a 20-centimeter
mass in the jejunum, which also involved the transverse
colon (Figure 1). She was proposed to elective surgery in
the same hospital admission. Laparotomy (August 6, 2014)
confirmed the jejunal mass; resection of the jejunal tumor
along with a segment of transverse colon was performed.
The postoperative period was uneventful and the patient was
discharged home on the 8th postoperative day.
Histopathological examination of the tumor revealed an
undifferentiated carcinoma (T3N0Mx). The lack of dysplasia
and atypia of the intestinal epithelium and the normal
glands surrounding themalignant cells favored diagnosis of a
metastatic lesion. Immunohistochemistry (IHC) performed
on the specimen was positive for cytokeratin 7 (CK7) and
CAM 5.2 (Figure 2) and negative for ER, PgR, and HER2
receptors, cytokeratin-20 (CK20), and gross cystic disease
fluid protein-15 (GCDFP-15). Histologic slides revision was
performed in other institutions with agreeing results: IHC
was negative for mammaglobin and GCDFP-15. GATA3
expression is not performed in both institutions. Notwith-
standing this, IHC along with morphological aspects of the
tumor were consistent with breast cancer metastases. Based
on these findings and the clinical history, we concluded this
was a jejunal metastasis from breast carcinoma.
The patient started on adjuvant chemotherapy inOctober
2, 2014, with 6 cycles of paclitaxel (175mg/m2) followed by
carboplatin (AUC 5–685mg), and ended it in January 27,
2015. She is disease-free for 20 months now.
3. Discussion
Metastases of breast cancer are commonly found in bone,
liver, lungs, and brain. Gastrointestinal (GI) metastases from
breast cancer are rare in clinical practice, with less than 1%
of breast cancer having GI metastases [7, 8]. Isolated GI
metastases without metastases to other organs are even rarer.
In the review by McLemore et al. [6], out of 12,001 cases
of metastatic breast cancer, only 23 cases had GI metastases
alone (0.2%). Autopsy series show that the occurrence of
GI metastases from breast cancer is more common, than
clinically suspected, reaching 30% of cases in some studies [3,
5]. However, most of these metastases are asymptomatic and,
therefore, not detected during follow-up andwith less clinical
relevance. When looking at breast cancer metastases to GI
tract, the patterns ofmetastatic spread are quite variable in the
literature, with small bowel being affected in 9–28% of cases
with GI metastases. A paper published in 2012 by Ambroggi
et al. analyzed the sites of GI breast cancer metastases. They
reviewed the literature and found the most common site of
GI metastases of breast cancer was the stomach (60%) and
followed by esophagus (12%), colon (11%), small bowel (8%),
and rectum (7%) [8].
Metastatic patterns vary according to histological types.
Although LC accounts for only 5–10% of invasive breast car-
cinoma, this histological subtype is the one more frequently
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Figure 2: Histologic and IHC study: (a) and (b) indifferenciated carcinoma (hematoxylin and eosin stain) and (c) and (d) positivity for CAM
5.2 and cytokeratin 7.
associated with metastases to the GIT [6–8]. Harris et al.
published a landmark study comparing metastatic pattern of
LC and DC [3]. He found that, in 76 cases of metastatic DC,
only 3 had intestinal metastases. He also found that LC was
prone tometastasize in amore “diffuse” fashion,withmultiple
tiny nodules that became confluent, while DC metastases
formed nodular masses. Our patient had a metastasis of
DC to the small bowel, which is a rare event but has been
described previously [6, 8–11].
With regard to time between breast cancer and GI metas-
tases diagnosis, most cases usually occur in the early years
after primary cancer diagnosis. Switzer et al. [12] reported
a median interval of 4 years between breast cancer and GI
metastases andMcLemore et al. [6] found amedian of 7 years.
Our patient presented with a metastasis occurring 12 years
after her primary breast cancer diagnosis. This is uncommon
but longer time periods have been published in the literature,
with GI metastases presenting as late as 30 years [13].
The correct diagnosis on this kind of clinical case can be a
hard challenge. First is the rarity of the condition that leads to
a low index of suspicion. Second, they can occur many years
after the original disease, especially with longer survival of
patients. Third, they have a nonspecific clinical presentation:
symptoms depend on localization and range widely from
a patient being relatively asymptomatic [9] to complaining of
vague nausea, abdominal pain [12], dysphagia [4], or more
alarming symptoms such as bleeding [14], bowel obstruction
[10, 15], perforation [16], or even appendicitis [17]. However,
even if GI metastases of breast cancer are rare, this diagnostic
hypothesis should be considered in any woman presenting
with a GI tumor and a history of breast cancer (regardless of
how remote).
Another issue is the pathological diagnosis. In fact,
distinguishing primary from metastatic GI tumors can be
difficult. Features typically used to make this distinction
include gross configuration of the tumor [4], careful evalu-
ation of the morphology of the lesion on histopathological
analysis, and, when possible, comparative review of slides
of prior cancer. All of those are as important as the clinical
history in diagnosis. Usually, morphology on slides is similar
enough to allow a diagnosis of metastatic breast cancer based
on comparative histologic review alone [18]. In IHC study,
carcinomas of breast origin are usually positive for CK7
and negative for CK20 (CK7+/CK20−), contrary to low GI
tumors that are almost always CK20 positive [19]. In the
present case the primary tumor and the metastasis are poorly
differentiated, making comparative histopathological study
difficult and renders IHC study poor diagnostic value. In
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fact, IHC alone should not be used, especially in metastases
of poorly differentiated cancers, which tend to lose tissue-
specific gene expression compared to those of the primary
tumor. Despite these limitations, our patient’s primary breast
cancer and the metastasis diagnosed 12 years later are both
CK7+/CK20−. Although changes in receptor status over
the course of disease have been described, in most cases
there is concordance between primary tumors and matching
metastasis [20]. This profile is seen in other tumors, such
as lung or the gynecologic malignancies; however, careful
attention to the clinical history and the morphologic findings
of the tumor favored a breast origin. In our case the GCDFP-
15 and mammaglobin were both negative.This is an expected
result, since in triple-negative breast cancer (TNBC)GCDFP-
15 is infrequently expressed when compared with other
breast cancer subtypes [21]. Also, diagnostic sensitivity of
GCDFP-15 is onlymoderate with reported rates of expression
in metastatic breast cancer ranging from 11% to 71% [21].
Mammaglobin is more sensitive than GCDFP-15 for breast
origin but less specific, being negative in 23–52% of locally
recurrent and metastatic breast carcinomas [21]. GATA3
seems to be particularly useful as a marker for metastatic
breast carcinoma, especially triple-negative and metaplastic
carcinomas, which lack specific markers of mammary origin
[22], but is not available in both institutions. Anyway, the IHC
results must be integrated with the morphologic and clinical
features to arrive at the correct diagnosis. In this case, the
lack of dysplasia or atypia of the intestinal epithelium and the
glands surrounding themalignant cells was an important fac-
tor in making the diagnosis of a metastatic lesion more likely.
So, our diagnosis of breast cancer metastasis was based
on the combination of available clinical history, histology,
and IHC. In this case, no isolated tissue marker was entirely
specific or sensitive, but their integration with clinical history
andmorphological findings allowed us tomake the diagnosis.
Regarding treatment options for metastatic breast cancer
patients, options are targeted therapies (endocrine therapy or
molecularly targeted agents such as trastuzumab or lapatinib)
or systemic chemotherapy. Choice of treatment will be
dictated by the IHC profile and patient’s symptoms. Patients
with TNBC lack known drug targets (ER, PgR, and HER2);
hence they are treated with chemotherapy [6, 8, 23]. Surgery
and radiotherapy are usually used with palliative intent, for
symptom relief [6]. Surgery is mainly indicated to treat com-
plications such as bleeding, perforation, or obstruction [6,
10, 15]. In selected cases, surgery may increase survival [24].
Survival rate of patients who undergo treatment averages 24
months and is being improved by new systemic therapies
[25]. In this case surgery was indicated due to intestinal
obstruction and adjuvant chemotherapy (carboplatin and
paclitaxel) was selected according to the diagnosis of triple-
negative breast cancer metastasis. Currently, 20 months into
follow-up, the patient is asymptomatic and free of known
disease recurrence.
This manuscript alerts clinicians to the importance of
being attentive to gastrointestinal symptoms in breast cancer
patients, no matter how long ago the breast cancer was diag-
nosed, as they can be the first sign of GI tract metastases.This
can lead to a correct diagnosis, which can allow the patient to
have the necessary treatment.The relevance of this case is also
related to the fact that diagnosis of breast cancermetastases to
GI tractmore than 5 years after initial cancer treatment can be
a challenge, especially if it is a singlemetastasis to GI tract of a
TNBC, in which case the IHC alone may not be enough for a
diagnosis. It was the combination of available clinical history,
histology, and IHC that allowed for a correct diagnosis.
4. Conclusion
Although rare, GIT breast cancer metastases can occur. It
is important for physicians to keep in mind that clinical
presentation is random and nonspecific, and that GI com-
plaints can occur years after initial disease. It should also
be remembered that this pattern of metastatic spread is not
limited to LC but may also be seen with the commoner
DC. Diagnosis should be quick and prompt intervention
guaranteed. Patients should be offered surgery in cases of
complication or for symptomatic relief.
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